クラミジア感染症(Chlamydia Infections):世界の治験レビュー(2014年下半期版)

◆英語タイトル:Chlamydia Infections Global Clinical Trials Review, H2, 2014
◆商品コード:GDHC2431CTIDB
◆発行会社(リサーチ会社):GlobalData
◆発行日:2014年11月28日
◆ページ数:67
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,000 ⇒換算¥520,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD7,500 ⇒換算¥780,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界におけるクラミジア感染症(Chlamydia Infections) 治療の臨床試験動向について調査・分析し、アジア太平洋/欧州/北米/中南米の主要国における治験件数、段階(フェーズ)別の治験件数、進捗状況別の治験件数、治験目標の達成状況、有望な薬剤、治験関連の最新ニュース、代表的な企業・大学・研究機関における治験概要、代表的な治験のプロファイルなどのデータをまとめてお届けいたします。

・イントロダクション
  - クラミジア感染症(Chlamydia Infections)
  - 当レポートの概要
・クラミジア感染症(Chlamydia Infections):各地域別治験状況
  - 各国の治験件数及び平均被験者数
   アジア太平洋の主要国における治験件数
   欧州の主要国における治験件数
   北米の主要国における治験件数
   中東・アフリカの主要国における治験件数
   中南米の主要国における治験件数
・G7諸国での治験件数
・G7諸国での治験件数:段階別
・G7諸国での治験件数:進捗状況別
・段階(フェーズ)別の治験件数:進行中の治験(段階別)
・進捗状況別の治験件数
・治験目標の達成状況
・未完了の治験件数
・一定期間に採用された被験者
・スポンサーの種類別治験件数
・有望なスポンサー
・有望な薬剤
・治験のプロファイル
  - 代表的な企業における治験概要
  - 代表的な大学・研究機関における治験概要
・5つの代表的な治験のプロファイル
【レポートの概要】

Chlamydia Infections Global Clinical Trials Review, H2, 2014

Summary

GlobalData’s clinical trial report, “Chlamydia Infections Global Clinical Trials Review, H2, 2014″ provides data on the Chlamydia Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chlamydia Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chlamydia Infections. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Chlamydia Infections 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Chlamydia Infections to Infectious Disease Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Chlamydia Infections to Infectious Disease Clinical Trials 18
Clinical Trials by Phase 19
In Progress Trials by Phase 20
Clinical Trials by Trial Status 21
Clinical Trials by End Point Status 22
Unaccomplished Trials of Chlamydia Infections 23
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Chlamydia Infections Therapeutics Clinical Trials 29
Prominent Drugs 30
Clinical Trial Profiles 31
Clinical Trial Overview of Top Companies 31
Kyorin Holdings, Inc. 31
Clinical Trial Overview of Kyorin Holdings, Inc. 31
Endo International plc 32
Clinical Trial Overview of Endo International plc 32
Cempra Pharmaceuticals, Inc. 33
Clinical Trial Overview of Cempra Pharmaceuticals, Inc. 33
ActivBiotics Pharma, LLC 34
Clinical Trial Overview of ActivBiotics Pharma, LLC 34
Actavis plc 35
Clinical Trial Overview of Actavis plc 35
Clinical Trial Overview of Top Institutes / Government 36
University of California, San Francisco 36
Clinical Trial Overview of University of California, San Francisco 36
Johns Hopkins University 37
Clinical Trial Overview of Johns Hopkins University 37
Centers for Disease Control and Prevention 38
Clinical Trial Overview of Centers for Disease Control and Prevention 38
National Heart, Lung, and Blood Institute 39
Clinical Trial Overview of National Heart, Lung, and Blood Institute 39
University of Pittsburgh 40
Clinical Trial Overview of University of Pittsburgh 40
The University of Melbourne 41
Clinical Trial Overview of The University of Melbourne 41
Washington University School of Medicine 42
Clinical Trial Overview of Washington University School of Medicine 42
London School of Hygiene & Tropical Medicine 43
Clinical Trial Overview of London School of Hygiene & Tropical Medicine 43
Population Council 44
Clinical Trial Overview of Population Council 44
Barts and The London NHS Trust 45
Clinical Trial Overview of Barts and The London NHS Trust 45
Five Key Clinical Profiles 46
Appendix 65
Abbreviations 65
Definitions 65
Research Methodology 66
Secondary Research 66
About GlobalData 67
Contact Us 67
Disclaimer 67
Source 67

List of Tables
Chlamydia Infections Therapeutics, Global, Clinical Trials by Region, 2014* 7
Chlamydia Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Chlamydia Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Chlamydia Infections Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Chlamydia Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Chlamydia Infections Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Chlamydia Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Chlamydia Infections Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Chlamydia Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Chlamydia Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Chlamydia Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Chlamydia Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Chlamydia Infections Therapeutics, Global, Clinical Trials by Phase, 2014* 19
Chlamydia Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 20
Chlamydia Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014* 21
Chlamydia Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014* 22
Chlamydia Infections Therapeutics, Global, Suspended Clinical Trials, 2014* 23
Chlamydia Infections Therapeutics, Global, Withdrawn Clinical Trials, 2014* 24
Chlamydia Infections Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Chlamydia Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Chlamydia Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Chlamydia Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Chlamydia Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Chlamydia Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Chlamydia Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Kyorin Holdings, Inc., 2014* 31
Chlamydia Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Endo International plc, 2014* 32
Chlamydia Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Cempra Pharmaceuticals, Inc., 2014* 33
Chlamydia Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by ActivBiotics Pharma, LLC, 2014* 34
Chlamydia Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Actavis plc, 2014* 35
Chlamydia Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014* 36
Chlamydia Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Johns Hopkins University, 2014* 37
Chlamydia Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Centers for Disease Control and Prevention, 2014* 38
Chlamydia Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014* 39
Chlamydia Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pittsburgh, 2014* 40
Chlamydia Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Melbourne, 2014* 41
Chlamydia Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014* 42
Chlamydia Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by London School of Hygiene & Tropical Medicine, 2014* 43
Chlamydia Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Population Council, 2014* 44
Chlamydia Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Barts and The London NHS Trust, 2014* 45

List of Figures
Chlamydia Infections Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Chlamydia Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Chlamydia Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Chlamydia Infections Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Chlamydia Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Chlamydia Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Chlamydia Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Proportion of Chlamydia Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Chlamydia Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Chlamydia Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Chlamydia Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Chlamydia Infections Therapeutics, Global, Clinical Trials by Phase (%), 2014* 19
Chlamydia Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 20
Chlamydia Infections Therapeutics, Global, Clinical Trials by Trial Status, 2014* 21
Chlamydia Infections Therapeutics Clinical Trials, Global, by End Point Status, 2014* 22
Chlamydia Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Chlamydia Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Chlamydia Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Chlamydia Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Chlamydia Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 66

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[クラミジア感染症(Chlamydia Infections):世界の治験レビュー(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆